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Abstract. Control of schistosomiasis presently relies largely on preventive chemotherapy with praziquantel through
mass drug administration (MDA) programs. The Schistosomiasis Consortium for Operational Research and Evaluation
has concluded ﬁve studies in four countries (Coˆte d’Ivoire, Kenya, Mozambique, and Tanzania) to evaluate alternative
approaches to MDA. Studies involved four intervention years, with ﬁnal evaluation in the ﬁfth year. Mass drug adminis-
trationgivenannually or twiceover 4 years reducedaverageprevalence and intensity of schistosome infections, but not all
villages that were treated in the sameway responded similarly. There aremultiple ways bywhich responsiveness toMDA,
or the lack thereof, could be measured. In the analyses presented here, we deﬁned persistent hotspots (PHS) as villages
that achieved less than 35% reduction in prevalence and/or less than 50% reduction in infection intensity after 4 years of
either school-basedor community-wideMDA, either annually or twice in 4 years. By this deﬁnition, at least 30%of villages
in each of the ﬁve studies were PHSs. We found no consistent relationship between PHSs and the type or frequency of
intervention, adequacy of reported MDA coverage, and prevalence or intensity of infection at baseline. New research is
warranted to identify PHSs after just one or a few rounds of MDA, and new adaptive strategies need to be advanced and
validated for turning PHSs into responder villages.
INTRODUCTION
The control of morbidity due to schistosomiasis and its
eventual elimination has been the focus of multiple World
Health Assembly (WHA) resolutions (e.g., WHA 54.19, WHA
65.21, and WHA 66.12)1–6 and is being pursued by many
neglected tropical disease (NTD) national programs in Africa,
Asia, the Middle East, and South America. The standard
approach used by most programs is preventive chemother-
apy by mass drug administration (MDA)7 using the anti-
schistosomal drug praziquantel (PZQ).8,9
To provide evidence regarding different ways to control
schistosomiasis through MDA, the Schistosomiasis Consor-
tium for Operational Research and Evaluation (SCORE;
https://score.uga.edu/) has conducted ﬁve studies in four
countries (i.e., Coˆte d’Ivoire, Kenya, Mozambique, and Tan-
zania) with harmonized protocols to evaluate alternative ap-
proaches to MDA. There were originally seven studies in ﬁve
countries, but two studies in one country had to be redesigned
because of protocol deviations in the randomization of study
villages. The remaining ﬁve studies involved four intervention
years, with ﬁnal evaluation in the ﬁfth year.10 In each of the ﬁve
studies, MDA, either by school-based treatment (SBT) or
community-wide treatment (CWT), and whether annual, bi-
ennial, or even with two consecutive years without treatment
(drug holiday years), reduced prevalence and intensity of in-
fection in the primary outcome group: schoolchildren aged 9
to 12 years. However, as previously reported for some of the
studies,11,12 the average reduction in prevalence and intensity
hide the fact that although many villages demonstrate the
expected decreases, others do not, and stubbornly remain
what we term persistent hotspots (PHSs). Spatial clusters or
hotspots have been recognized in infectious disease epide-
miology in various contexts to describe an area of higher
burden of disease or higher transmission of disease.13 For
instance, malaria transmission is known to be higher in hot-
spots, and it is recognized that elimination of these residual
foci will be necessary for malaria elimination.14–17 Studies of
schistosomiasis programs also show that some communities
remain at persistently high prevalence despite MDA.18–23 The
designation of PHSs intentionally includes the concept of
“persistence,” that is, a location that remains at high preva-
lence and/or infection intensity in the face of consistent pre-
ventive chemotherapy with reasonably high coverage.
There is presently no standard deﬁnition of PHSs, and, in
fact, it is likely that the optimal deﬁnition may vary by the data
available, the site surveyed, the programmatic goal, or other
contextual factors. Previously,weevaluatedhow four different
* Address correspondence toDaniel G. Colley, Center for Tropical and
Emerging Global Diseases, 500 DW Brooks Dr., Rm. 330B Coverdell
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deﬁnitions for PHSswould affect characterization of villages in
theSCOREstudy inTanzania.11 Thepresent studyusesoneof
these deﬁnitions—one we believe may be useful in many
settings—to determine the proportion of PHSs in all ﬁve of the
SCORE gaining and sustaining studies, and to evaluate
whether the occurrence of PHSs correlates with parameters
such as starting prevalence, intensity, and reported coverage.
We also examinewhether a village’s status as a PHSafter 1, 2,
or 3 years of MDA predicts its status after 4 years. Given the
known focal nature of schistosomiasis transmission and the
heterogeneities associated with many vector-transmitted
diseases,24 the ﬁnding of PHSs within these large SCORE
studies should, perhaps, not have been unexpected. Never-
theless, the existence and documentation of PHSs indicate
the importance of detecting them and adjusting strategies to
deal with them to accomplish schistosomiasis control to ef-
fectively move to elimination. The objective of this study was
to compare and contrast data on PHSs from several different
studies to get a clearer andmore generalizable understanding
of PHSs during MDA treatment for schistosomasis.
METHODS
Study data and study arms. Data from the ﬁve large,
multicenter SCORE gaining and sustaining studies were
used to evaluate PHSs in this article. A description of the
overall study, its methods, and baseline data have been
published.10,25–30 In brief, the sustaining control studies in
Coˆte d’Ivoire and Kenya compared villages that were shown
in eligibility testing to have schistosomiasis prevalence of
10–24%. There were three study arms, with 25 villages per
arm. Arm 1 received annual MDA by SBT, arm 2 received
annual SBT for 2 years followed by two drug holiday years,
and arm 3 received SBT every other year. Both of these
sustaining control studies focused on the control of Schis-
tosoma mansoni.
The gaining control studies were conducted in villages with
prevalence ³ 25% in eligibility testing in Kenya and Tanzania
(S. mansoni) and Mozambique (Schistosoma haematobium).
These studies had six study arms, each with 25 villages. Arms
1, 2, and 4 received annualMDAby either CWTor SBT. Arms 3
and 5 received 2 years of MDA followed by 2 years of drug
holiday. Arm 6 received MDA every other year. The study di-
agram is shown in Supplemental Figure 1. All villages had
annual measurement of prevalence and intensity, except for
years when the village had a drug holiday.
Study participants anddata collection. The primary study
population in these SCORE studies was 9- to 12-year-old
children. During the baseline and ﬁnal study years that are
described in this article, 100 children aged 9–12 years were
surveyed in each study village. For the annual cross-sectional
prevalence and intensity assessment ofS.mansoni in 9- to 12-
year-old children, stool specimens were collected on three
consecutive days from each child and eggs were counted on
FIGURE 1. Prevalence by infection intensity category in ﬁve Schistosomiasis Consortium for Operational Research and Evaluation studies, by
study arm. Data from baseline year (Y1) and ﬁnal survey (Y5) are shown. In study arm notations, c refers to community-wide treatment, s refers to
school-based treatment, and h refers to drug holiday year. χ2 P-value is < 0.05 for comparisons of Y1 and Y5 in all arms of all studies. COT = Coˆte
d’Ivoire; KEN = Kenya; MOZ = Mozambique; TAN = Tanzania.
618 KITTUR AND OTHERS
duplicate Kato–Katz thick smears per specimen. For
S. haematobium prevalence and intensity surveys, two 10-mL
aliquots from a single midday urine specimen were ﬁltered,
and the ﬁlters examined quantitatively under a microscope by
two independent experienced laboratory technicians for
S. haematobium eggs.
Ethical approval and consent to participate. Written in-
formed consent was obtained from adults (including
parents/legal guardians of children in the study), and assent
was obtained from children less than 18 years, except in
places where village-level consent is the standard, in which
case local requirementsweremet. Ethical reviewof research
protocol was implemented by human subjects committee in
each African country and by the institutional review board
(IRB) of their respective northern partners. Studies of gaining
and sustaining control of schistosomiasis in Kenya were
reviewed and approved by the National Ethics Review
Committee of the Kenyan Medical Research Institute (ap-
proval numbers SCC 1800 and SCC 1820, respectively) and
by the IRB of the CDC (approval no.: 1661). For the study of
sustaining control in Coˆte d’Ivoire, ethical approval was
obtained from the ethics committees in Coˆte d’Ivoire (ref-
erence no. 1994MSHP/CNER) and Basel (reference no.
EKBB 279/10). In Mozambique, ethical approval was re-
ceived from theMinistry of Health (reference no. 235/CNBS/
10) and the Imperial College Research Ethic Committee
(ICREC_10_8_2). In Tanzania, ethical approval was obtained
from the National Institute for Medical Research (NIMR;
reference no. NIMR/HQ/R.8a/Vol. IX/1022). In addition to
these, the University of Georgia IRB implemented an
administrative human subject’s review and issued addi-
tional approval as per country’s protocol as follows:
10021–0, 10221–0, 10267–0, 10353–0, and 10533–0 for
Coˆte d’Ivoire, Kenya sustaining study, Kenya gaining study,
Tanzania, and Mozambique, respectively.
The trials have been registered with the International Stan-
dard Randomized Controlled Trial registry under ISRCT
numbers 99401114 (Coˆte d’Ivoire), 14849830 (Kenya Sm1),
16755535 (Kenya Sm2), 95819193 (Tanzania), 32045736
(Niger), and 14117624 (Mozambique).
Persistent hotspots. For the analyses herein, we deﬁne a
PHS as a village that fails to reduce in prevalence by at least
35% and/or fails to reduce in intensity by at least 50% be-
tween baseline and year ﬁve testing. Although these cutoffs
were arbitrarily selected, they were based on the box plots of
the percent change in prevalence and intensity in all ﬁve
studies, shown in Supplemental Figure 2. The reasons for
selection of these cutoffs are as follows: it would appear that if
an NTD program fails to achieve a one-third decrease in
prevalence and/or a one-half decrease in intensity of infection
in a given village, then that village deserves additional atten-
tionboth in regard to thehealth of its occupants and in termsof
achieving program goals, and should be designated a PHS.
Coverage. For the present analysis, adequate coverage in
both SBT and CWT villages was deﬁned as ³ 50% reported
coverage of school-age children during the 1st year of MDA
and ³ 75% reported coverage in all subsequent years.
Data handling and analysis. Data analysis was performed
using IBM SPSS Statistics for Windows (Version 25.0; IBM
Corp., Armonk, NY). Graphs were generated using GraphPad
FIGURE 2. (Top) Mean prevalence at baseline (Y1) and ﬁnal survey (Y5) in study arms that received 4 years of annual school-based treatment and
(bottom) line graphs showing changes in prevalence in individual villages in the same respective study arms. Gray lines depict villages that showed
³ 35% reduction in prevalence (responders), whereas black lines depict villages with < 35% reduction in prevalence from baseline to year 5 (persis-
tent hotspots based on change in prevalence). COT = Coˆte d’Ivoire; KEN = Kenya; MOZ = Mozambique; TAN = Tanzania.
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Prism version 7.0 for Windows (GraphPad Software, La Jolla,
CA). Consistent with guidelines put forward by the WHO,
S. mansoni infection intensity was classiﬁed as follows: indi-
viduals with < 100 eggs per gram (EPG) were considered to
have light infections, those with 100–399 EPG to have mod-
erate intensity infections, and those with ³ 400 EPG to have
heavy infections. For S. haematobium, individuals with < 50
eggs/10 mL of urine were considered to have light infection
and those with ³ 50 eggs/10 mL to have heavy infections.31
The association between PHSs and two times versus four
times MDA, and between PHSs and adequate coverage was
assessed using Pearson X2 tests, whereas the association
between PHSs and baseline prevalence of heavy infections
was examined using the Mann–Whitney U test. All tests and
conﬁdence intervals used the 5% level of signiﬁcance.
RESULTS
Impact of MDA on prevalence and intensity of
schistosomiasis. In each of the SCORE gaining and sus-
taining studies, PZQ MDA was administered either as SBT or
CWT, and conducted annually or twice during 4 years. After
the 4 years, average levels of prevalence and intensity of
schistosomiasis among 9–12-year-old children were signiﬁ-
cantly lower in all study arms (Figure 1).
However, these averages conceal the fact that there is
considerable heterogeneity in the effectiveness of the
responses of individual villages among the different MDA
regimens. Figure 2 presents an example of this heterogeneity
using the study arm that received annual SBT for 4 years,
which corresponds to arm 1 of the sustaining studies and arm
4 of the gaining studies. The line graphs (bottom row) in
Figure 2 demonstrate the spectrum of change in prevalence
among the villages that received 4 years of annual SBT. Eight
(32%) of the 25 villages in annual SBT arms of both the Coˆte
d’Ivoire sustaining study and theKenya sustaining study show
only slight decreases or even increases in prevalence over the
study period. Increases or slight decreases in prevalences are
also seen in the annual SBT arm in ﬁve of 25 (20%) villages in
the Kenya gaining study, in 16 of 25 (64%) villages in the
Tanzania gaining study, and in seven of 21 (33.3%) villages in
the Mozambique gaining study. A similar variability in village
responses to MDA appeared in every arm in each of all ﬁve
studies—although most villages demonstrate reduced prev-
alence by year 5, some decrease only slightly, and some ac-
tually increase.
Figure 3 shows scatterplots of the percent change in prev-
alence (x axis) and intensity (y axis) from baseline to the end of
the study for each individual village in each of the ﬁve studies.
The dotted lines are set at x = 0 and y = 0. Villages in the boxes
denoted by the solid lines are those considered to be re-
sponder villages. Villages in the other three quadrants failed
either to demonstrate reductions of 35% in prevalence or 50%
in intensity, or both, and are, based on changes in both
FIGURE 3. Percent change in prevalence and intensity frombaseline (Y1) to ﬁnal (Y5) survey in individual villages in Schistosomiasis Consortium
for Operational Research and Evaluation studies. Each point depicts a study village. The x axis shows percent change in prevalence and the
y axis shows percent change in intensity. Dotted lines are set at x = 0 and y = 0. The solid lines show the cutoffs for our deﬁnition of persistent
hotspots (PHSs): Thirty-ﬁve percentage reduction in prevalence and 50% reduction in intensity. Dots in the box indicate responding villages,
whereas all others are classiﬁed as PHSs on the basis of prevalence, intensity, or both. COT =Coˆte d’Ivoire; KEN = Kenya; MOZ =Mozambique;
TAN = Tanzania.
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prevalence and intensity, consideredPHS villages. In theCoˆte
d’Ivoire sustaining control study, nearly half (34 of 75, 45.3%)
study villages were PHSs and most PHSs (73.5%) met the
PHS deﬁnition based on prevalence alone, whereas the rest
(26.5%) failed to reduce adequately in both prevalence and
intensity. In the sustaining control study in Kenya, 41 of 75
study villages (54.7%) were PHSs. Of these, most (41.5%)
were classiﬁed as PHSs based on their limited reduction in
intensity, whereas 36.6% failed to decrease in both preva-
lence and intensity and 22% failed to decrease in prevalence
alone. In the Kenya gaining control study, 35.3% (53 of 150)
study villages were PHSs, with 43.4% of PHSs failing in terms
of both prevalence and intensity, 35.8% failing in terms of
prevalence alone, and 20.8% failing to decrease adequately in
FIGURE 4. Geographical distribution of persistent hotspots (red circles) and responding villages (yellow triangles) in study areas. Major cities and
water bodies are indicated.COT=Coˆte d’Ivoire; KEN=Kenya;MOZ=Mozambique; TAN=Tanzania. This ﬁgure appears in color atwww.ajtmh.org.
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intensity. The Tanzania gaining control study had 106 of 148
study villages (71.6%) classiﬁed as PHSs, with most PHSs
(54.7%) meeting the deﬁnition based on limited reduction in
both prevalence and intensity, whereas 34% failed to de-
crease by prevalence alone and 11.3% failed to decrease by
intensity alone. The Mozambique gaining study similarly
showed a high proportion of PHSs in 87 of 133 study villages
(65.4%), withmost of these (4.1%)meeting the PHS deﬁnition
on both intensity and prevalence, whereas 34.5% failed to
decrease in intensity alone and 18.4% failed to decrease in
prevalence alone.
The geographical distribution of PHSs and responding vil-
lages in the ﬁve studies is shown in Figure 4. Themaps show a
spatial clustering of PHSs in the Kenya gaining study, an ob-
servation that hasbeenconﬁrmedbygeospatial analysis.12By
contrast, the Tanzania and Mozambique gaining studies and
theCoˆte d’Ivoire andKenya sustaining studies showa random
distribution of PHSs and responding villages.
Figure 5 presents the proportion of villages, by arm, that
meet our deﬁnition of PHSs based on both prevalence and
intensity of infection at year 5. It can be seen that all arms of
the ﬁve studies contain PHSs. In the sustaining studies,
30–60% of villages remained PHSs at year 5. There were dif-
ferences in PHS ﬁndings among the gaining studies seen at
the end of the study. In Kenya, 20–50%villages were PHSs. In
Mozambique, 65–80% of villages were PHSs, but arms with
annual CWT or annual CWT/SBT regimens (arms 1 and 2,
respectively) had fewer PHSs than the other arms (Figure 4).
In Tanzania, in year 5, all arms had more than 60% PHSs,
which was higher than expected based on previously report-
ed Tanzania year 4 data.11
Relationship betweendrug holidays andPHSs.Although
PHSs occurred in all arms in all SCORE sustaining and gaining
control studies, study arms having four MDA treatments had
fewer PHSs than those that received only two MDAs over the
study period. Although the trend is seen in all studies (Table 1),
this result was statistically signiﬁcant only in theKenyagaining
control study (P = 0.008) and approaches but does not reach
statistical signiﬁcance in the Coˆte d’Ivoire sustaining study
(P = 0.081).
Further analyses examined the impact of two consecutive
MDAs followed by two drug holidays on the number of PHSs.
Two MDAs followed by two drug holiday years resulted in
more PHSs than MDA without two consecutive drug holidays
(Table 2). However, again, the difference was only statistically
signiﬁcant in theKenyagaining study (P=0.041) (Table 2). This
trend was clear but did not achieve statistical signiﬁcance in
the Coˆte d’Ivoire sustaining study and the Mozambique
gaining study (P = 0.060).
Relationship between MDA coverage and PHSs. One
possible explanation for PHSs could be low levels of reported
MDA coverage. For these analyses, adequate coverage was
deﬁned as ³ 50% school-age children treated in year 1
and ³ 75% in subsequent years, for both SBT and CWT vil-
lages. All villages in the Kenya sustaining study met the deﬁ-
nition of adequate coverage; nevertheless, almost 50% of the
FIGURE 5. Percent of study villages in each study arm thatmet the prevalence and intensity deﬁnition for persistent hotspots (PHSs) in year 5. COT=
Coˆte d’Ivoire; KEN = Kenya; MOZ = Mozambique; TAN = Tanzania.
TABLE 1
Comparison of proportion of PHSs in year 5 in the study arms that had
mass drug administration (MDA) every year (4×) vs. those that had
MDA twice in 4 years (2×)
PHSs in 2× arms (%) PHSs in 4× arms (%) P-value
COT sustaining 52.0 32.0 0.081
KEN sustaining 56.0 52.0 0.743
KEN gaining 45.3 25.3 0.008*
TAN gaining 73.0 70.3 0.715
MOZ gaining 71.6 59.1 0.128
COT = Coˆte d’Ivoire; KEN = Kenya; MOZ = Mozambique, PHSs = persistent hotspots;
TAN = Tanzania. χ2 P-value is indicated.
* Statistical signiﬁcance (P < 0.05).
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villages in each arm were categorized as PHSs (Figure 5). In
the other four studies, where this level of coverage was not
reportedly uniformly achieved, the proportion of villages that
were PHSs was similar, regardless of whether or not a village
attained adequate coverage (Figure 6).
PredictingPHSsbasedonprevalenceand intensity data
before year 5. Another issue we explored was whether
baseline prevalence or intensity was related to the likelihood
that a village would respond well to MDA or become a PHS.
Figure 7 indicates that the median starting prevalence of PHS
villages in the Kenya gaining study was signiﬁcantly higher
than those that became responder villages. Conversely, in the
Kenya sustaining study, although the median starting preva-
lence differed between PHSs and responder villages, the re-
sponder villages had the higher starting prevalence. There
were no statistically signiﬁcant differences related to starting
prevalence in the studies in Coˆte d’Ivoire, Tanzania or
Mozambique.
Figure 8 demonstrates that the starting prevalence of heavy
infections was a statistically signiﬁcant predictor that a village
wouldbe aPHSonly in thegaining control study inKenya. This
relationship was not statistically signiﬁcant in the other four
studies.
We explored whether data from years other than year 1
predicted PHSs by examining villages that received annual
SBT—corresponding to arm 1 in the sustaining and arm 4 in
the gaining control studies. These study arms were chosen
because annual SBT is the only annual treatment regimen
implemented in both the gaining and sustaining studies.
Prevalence and intensity categories for responding villages
and PHSs in annual SBT arms are shown in Figure 9 for all
study years and for all studies. For the studies of sustaining
control (starting prevalence 10–24%), ﬁndings differed by
country. In the Coˆte d’Ivoire sustaining control study, future
status could be determined bymonitoring after 1 year ofMDA,
before the year 2 MDA. However, in the Kenya sustaining
TABLE 2
Comparison of proportion of PHSs in study arms that had two consecutive drug holidays vs. those that did not
PHSs in arms with two consecutive
drug holiday years (%)
% PHSs in arms that did not have two consecutive
drug holiday years (%) P-value
COT sustaining 60.0 38.0 0.060
KEN sustaining 64.0 50.0 0.251
KEN gaining 46.0 30.0 0.041*
TAN gaining 75.5 69.7 0.545
MOZ gaining 76.1 59.8 0.060
COT = Coˆte d’Ivoire; KEN = Kenya; MOZ = Mozambique, PHSs = persistent hotspots; TAN = Tanzania. χ2 P-value is indicated.
* Statistical signiﬁcance (P < 0.05).
FIGURE 6. Comparison of proportion of persistent hotspots (PHSs) in villages that had adequate mass drug administration (MDA) coverage
throughout the study versus villages that failed to have adequate coverage during one or moreMDA. χ2 P-value is indicated. The Kenya sustaining
control study is not included because all villages achieved adequate coverage. COT = Coˆte d’Ivoire; KEN = Kenya; MOZ = Mozambique; TAN =
Tanzania.
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study, village responsebefore year 5wasnot predictive of ﬁnal
status as a PHS, as prevalencewas low in both responder and
PHS villages in the Kenya sustaining control study in year 2. In
the studies of gaining control where starting prevalence levels
were ³ 25%, assessment before the MDA in year 2 or year 3
would likely have predicted which villages would be catego-
rized as responders or PHSs when determined at year 5. In-
deed, in Mozambique and Kenya, it seems that a prediction of
which villages were to be become PHSs was possible after
just 1 year of MDA.
DISCUSSION
The SCORE studies of sustaining and gaining control of
schistosomiasis explored the question of whether different
regimens ofMDAwould lead to different amounts of reduction
in prevalence and intensity of schistosomiasis.10 The main
study ﬁndingwas that although all regimens decreasedoverall
prevalence and intensity, only a few statistically signiﬁcant
differences were observed between impacts of different
regimens.26,29,32 However, the observed arm-to-arm de-
creases represent an average of widely heterogeneous re-
sponses to MDA at the individual village level. Thus, although
the overall impact of an MDA program may appear satisfac-
tory, many villages (at least 30% in each of these ﬁve large
studies) may not have appreciable reduction in the prevalence
and/or intensity of schistosome infections, and may, there-
fore, need additional efforts to reduce infection proportions
and/or levels. Meanwhile, other villages that make up the av-
erage response to any givenMDAmayhavemarked reduction
in prevalence and intensity after just a year or two of in-
tervention that could perhaps allow adjustments to less in-
tensive MDA in subsequent years.
Our results indicate that PHSs occur both in areas that start
out with relatively low prevalence among schoolchildren
(10–24%) and those that start out higher (³ 25%). Whether a
village will become a PHS cannot consistently be predicted
based on the baseline prevalence or the starting prevalence of
heavy infections.
Persistent hotspots occurred in all study arms, even in those
with annual CWT. In some cases, there was an indication that
four annual MDAs resulted in a lower proportion of PHSs than
did two MDAs over 4 years; similarly, in some cases, having
MDA at least every other year resulted in fewer PHSs than
having two consecutive drug holidays.
Obviously, low MDA coverage can be expected to yield
poor outcomes. However, in these studies, the coverage
goals were high, nevertheless, achieving these levels of MDA
coverage did not seem to be associated with the likelihood of
being a PHS. The reliability of some of the coverage data in
these studies has been questioned (S. Binder, personal
communication); however, reported coverage was generally
substantial and coverage data were likely better than would
typically be available to most NTD programs. So, the
existence of around 30% PHSs after 4 years of MDA with
reported high coverage may represent a best-case scenario
for ongoing routine MDA programs directed at controlling
schistosomiasis.
Based on these analyses, the regimen or frequency of the
MDA, the adequacy of MDA coverage, or the overall
FIGURE 7. Box plots showing baseline (Y1) prevalence in villages that were responders and those that were persistent hotspots (PHSs) at the end
of the study (Y5). Mann–Whitney U-test P-values are indicated. COT = Coˆte d’Ivoire; KEN = Kenya; MOZ = Mozambique; TAN = Tanzania.
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prevalence or prevalence of heavy infections at baseline
does not seem to inﬂuence whether villages remain PHSs. It
is likely that whether or not a village remains a PHS in the face
of MDA-based control rests on the elusive characteristic
termed “the force of transmission” at that location. Indeed,
modeling studies have suggested that heterogeneous
transmission is likely to be a critical determinant of the epi-
demiology of vector-borne infections.24 It is widely ac-
knowledged that schistosomiasis is a focal disease and it is
clear that biological ampliﬁcation through intermediate host
snails, open water sources that serve as both people and
snail habitat, and socioeconomic realities such as sanitation
and human behavior contribute to the force of transmission. It
might be expected that village-to-village differences in these
parameters could explain differences between PHSs and
responding villages in the face of comparable MDA strategies.
Presently, several studies are ongoing to determine village
characteristics that correlate with being a PHS or a responder
village (e.g., R. Musuva, personal communication). In some
places, a combination of data types, including infection prev-
alence and intensity, sanitation, and environmental data, may
be predictive of sites that are likely to be PHSs.
Pending the results of ongoing studies of the characteristics
that deﬁne PHSs versus responder villages, several issues
arise that call for efforts by both investigators andNTD control
program managers. The ﬁrst is to determine the earliest time
point in an MDA program that will consistently indicate that a
given village is not responding as expected and is likely to be a
PHS. Current WHO guidelines indicate that programmatic
impact assessments of MDAs for control of schistosomiasis
be performed after 5 or 6 years.33 Although monitoring after 5
or 6 years may be sufﬁcient for diseases such as lymphatic
ﬁlariasis, our data show that this is not optimal for schistoso-
miasis: waiting for 5 years would leavemany villages with high
prevalence and intensity, with consequent effect on the health
of residents. It alsomay result in use of resources in responder
villages that donot require the same level of attention, and loss
of the opportunity to reallocate resources to areas of greater
need. Earlier impact assessmentsmay also require changes in
assessment strategies. It is conceivable that sentinel site
evaluations or limited sampling strategies would not be sufﬁ-
cient to detect highly focal PHSs and new strategies will need
to be developed and rigorously validated in different settings.
The second issue is, once identiﬁed, determining what can
be done to change a PHS into a responder village. Data such
as those reported here suggest that strategies that increase
MDA frequency (e.g., from every other year to every year) in
PHSs while perhaps decreasing them in responder villages
might be possible without worsening overall program out-
comes. Comprehensive approaches to PHSs, possibly add-
ing snail control, facilitating sanitation improvements and
behavioral change efforts, also need to be tested.
These large, longitudinal SCORE sustaining and gaining
studies of MDA implementation in different sub-Saharan
African countries have shown, as have prior studies, that
MDA does indeed lower the prevalence and intensity of
schistosome infections. The size of these SCORE studies
has, in addition, made it possible to demonstrate that fo-
cusing on the average impact observed obscures many in-
equities with regard to how individual villages respond to
MDA. This ﬁnding has implications for what will be needed to
achieve even and equitable control and what will be required
to achieve the stated ultimate goal of elimination of trans-
mission of schistosomiasis.
FIGURE 8. Box plots showing baseline (Y1) prevalence of heavy infections in villages that were responders and those that were persistent hotspots
(PHSs) at Y5. Mann–Whitney U-test P-values are indicated. COT = Coˆte d’Ivoire; KEN = Kenya; MOZ = Mozambique; NS = not signiﬁcant; TAN =
Tanzania (P > 0.05).
SCHISTOSOMIASIS PERSISTENT HOTSPOTS 625
Received March 8, 2019. Accepted for publication May 24, 2019.
Published online July 8, 2019.
Note: Supplemental ﬁgures appear at www.ajtmh.org.
Acknowledgments: We gratefully acknowledge the children and
adults who participated in this study.
Financial support: These studies received ﬁnancial support from the
University ofGeorgiaResearchFoundation, Inc., whichwas fundedby
the Bill & Melinda Gates Foundation for the SCORE project.
Disclaimer: The ﬁndings and conclusions in this report are those of
the authors and do not necessarily represent the ofﬁcial position of
the CDC.
Authors’ addresses: Nupur Kittur, Carl H. Campbell Jr., Sue Binder, and
Daniel G. Colley, Schistosomiasis Consortium for Operational Research
and Evaluation, University of Georgia, Athens, GA, E-mails: nkittur@
uga.edu, ccamp@uga.edu, suebinder1@gmail.com, and dcolley@
uga.edu. Charles H. King, Center for Global Health and Diseases,
CWRUSchool ofMedicine,Cleveland,OH, E-mail: chk@cwru.edu. Safari
Kinung’hi, Mwanza Research Centre, National Institute for Medical Re-
search, Mwanza, Tanzania, E-mail: kinunghi_csm@hotmail.com. Pauline
N. M. Mwinzi, Centre for Global Health Research, Kenya Medical Re-
search Institute, Kisumu, Kenya, E-mail: pmwinzi65@gmail.com. Diana
M. S. Karanja, Neglected Tropical Diseases Branch, Centre for Global
Health Research, Kenya Medical Research Institute, Kisumu, Kenya,
E-mail: dkaranja@kemricdc.org.EliezerK.N’Goran,Unite´ deFormationet
de Recherche Biosciences, Universite´ Fe´lix Houphoue¨t-Boigny, Abidjan,
Coˆte d’Ivoire, E-mail: eliezerngoran@yahoo.fr. Anna E. Phillips, De-
partment of Infectious Disease Epidemiology, London Centre for
Neglected Tropical DiseaseResearch, Imperial College London, London,
UnitedKingdom,E-mail: a.phillips05@imperial.ac.uk.PedroH.Gazzinelli-
Guimaraes, National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, MD, E-mail: pedrogazzinelli@
yahoo.com.br. Annette Olsen and Pascal Magnussen, Faculty of
Health andMedical Sciences,University ofCopenhagen, Copenhagen,
Denmark, E-mails: aol@sund.ku.dk and pma@sund.ku.dk. W. Evan
Secor and Susan P. Montgomery, Parasitic Diseases Branch, Division
of Parasitic Diseases and Malaria, Centers for Disease Control and
Prevention, Atlanta, GA, E-mails: was4@cdc.gov and zqu6@cdc.gov,
Juerg Utzinger, Swiss Tropical and Public Health Institute, Basel,
Switzerland, and University of Basel, Basel, Switzerland, E-mail:
juerg.utzinger@swisstph.ch. Joseph W. Walker, Odum School of
Ecology, University of Georgia, Athens, GA, E-mail: joewalker127@
gmail.com.
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.
REFERENCES
1. World Health Organization, 2001. Fifty-Fourth World Health
Assembly Resolution WHA54.19 Schistosomiasis and
Soil-Transmitted Helminth Infections. Geneva, Switzerland:
World Health Organization Fifty-Fourth World Health
Assembly.
2. World Health Organization, 2012. Sixty-Fifth World Health As-
sembly Resolution WHA65.21 Elimination of Schistosomiasis.
Geneva, Switzerland: World Health Organization Sixty-Fifth
World Health Assembly.
3. World Health Organization, 2013. Sixty-Sixth World Health As-
sembly Resolution WHA66.12 Neglected Tropical Diseases.
Geneva, Switzerland: World Health Organization Sixty-Sixth
World Health Assembly.
4. Colley DG, Bustinduy AL, Secor WE, King CH, 2014. Human
schistosomiasis. Lancet 383: 2253–2264.
5. French MD et al., 2018. Schistosomiasis in Africa: improving
strategies for long-term and sustainable morbidity control.
PLoS Negl Trop Dis 12: e0006484.
FIGURE 9. Prevalence and intensity categories for every study year among villages in study arms that received four annual school-based
treatments across the 5 years for SchistosomiasisConsortium forOperational Research andEvaluation studies of sustaining andgaining control,
stratiﬁed into responding villages (Resp) and persistent hotspots (PHSs). COT = Coˆte d’Ivoire; KEN = Kenya; MOZ = Mozambique; TAN =
Tanzania.
626 KITTUR AND OTHERS
6. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ,
Zhou XN, 2018. Schistosomiasis. Nat Rev Dis Primers 4: 13.
7. World Health Organization, 2006. Preventive Chemotherapy
in Human Helminthiasis: Coordinated Use of Anthelminthic
Drugs in Control Interventions: A Manual for Health Profes-
sionals andProgrammeManagers. Geneva,Switzerland:WHO.
8. Andrade G, Bertsch DJ, Gazzinelli A, King CH, 2017. Decline in
infection-related morbidities following drug-mediated reduc-
tions in the intensity of Schistosoma infection: a systematic
review and meta-analysis. PLoS Negl Trop Dis 11: e0005372.
9. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F,
Tukahebwa EM, Fleming FM, Zhang Y, Webster JP, Stothard
JR, Fenwick A, 2007. Impact of a national helminth control
programme on infection and morbidity in Ugandan school-
children. Bull World Health Organ 85: 91–99.
10. Ezeamama AE et al., 2016. Gaining and sustaining schistosomi-
asis control: study protocol and baseline data prior to different
treatment strategies in ﬁve African countries. BMC Infect Dis
16: 229.
11. Kittur N, Binder S, Campbell CH, King CH, Kinung’hi S, Olsen A,
Magnussen P, Colley DG, 2017. Deﬁning persistent hotspots:
areas that fail to decrease meaningfully in prevalence after
multiple years ofmassdrug administrationwith praziquantel for
control of schistosomiasis.AmJTropMedHyg 97:1810–1817.
12. Wiegand RE et al., 2017. A persistent hotspot of Schistosoma
mansoni infection in a ﬁve-year randomized trial of praziquantel
preventative chemotherapy strategies. J Infect Dis 216: 1425–1433.
13. Lessler J, Azman AS, McKay HS, Moore SM, 2017. What is a
hotspot anyway? Am J Trop Med Hyg 96: 1270–1273.
14. Bousema T et al., 2010. Identiﬁcation of hot spots of malaria
transmission for targeted malaria control. J Infect Dis 201:
1764–1774.
15. Bousema T, Grifﬁn JT, Sauerwein RW, Smith DL, Churcher TS,
Takken W, Ghani A, Drakeley C, Gosling R, 2012. Hitting hot-
spots: spatial targeting of malaria for control and elimination.
PLoS Med 9: e1001165.
16. World Health Organization, 2007. Guidelines on the Elimination
of Residual Foci of Malaria Transmission. World Health Or-
ganization, Regional Ofﬁce for the Eastern Mediterranean.
17. Srivastava A, Nagpal BN, Joshi PL, Paliwal JC, Dash AP, 2009.
Identiﬁcation of malaria hot spots for focused intervention in
tribal state of India: a GIS based approach. Int J Health Geogr
8: 30.
18. Ahmed AM, El Tash LA, Mohamed EY, Adam I, 2012. High levels
of Schistosoma mansoni infections among schoolchildren in
central Sudan one year after treatment with praziquantel.
J Helminthol 86: 228–232.
19. ClementsAC,Bosque-Oliva E, SackoM, LandoureA,DembeleR,
TraoreM,CoulibalyG,Gabrielli AF, FenwickA,BrookerS, 2009.
A comparative study of the spatial distribution of schistoso-
miasis in Mali in 1984–1989 and 2004–2006. PLoS Negl Trop
Dis 3: e431.
20. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y,
Sellin B, Donnelly CA, Fenwick A, Webster JP, 2007. Schisto-
soma haematobium infection and morbidity before and after
large-scale administration of praziquantel in Burkina Faso.
J Infect Dis 196: 659–669.
21. Landoure A et al., 2012. Signiﬁcantly reduced intensity of infec-
tion but persistent prevalence of schistosomiasis in a highly
endemic region in Mali after repeated treatment. PLoS Negl
Trop Dis 6: e1774.
22. PoggenseeG, Krantz I, Nordin P,Mtweve S, Ahlberg B,MoshaG,
Freudenthal S, 2005. A six-year follow-up of schoolchildren for
urinary and intestinal schistosomiasis and soil-transmitted
helminthiasis in northern Tanzania. Acta Trop 93: 131–140.
23. Satayathum SA, Muchiri EM, Ouma JH, Whalen CC, King CH,
2006. Factors affecting infection or reinfection with Schisto-
soma haematobium in coastal Kenya: survival analysis during a
nine-year, school-based treatment program. Am J Trop Med
Hyg 75: 83–92.
24. Woolhouse ME, Etard JF, Dietz K, Ndhlovu PD, Chandiwana SK,
1998. Heterogeneities in schistosome transmission dynamics
and control. Parasitology 117: 475–482.
25. Assare RK et al., 2014. Sustaining control of schistosomiasis
mansoni inmoderate endemicity areas inwesternCoted’Ivoire:
a SCORE study protocol. BMC Public Health 14: 1290.
26. Karanja DMS, Awino EK, Wiegand RE, Okoth E, Abudho BO,
Mwinzi PNM, Montgomery SP, Secor WE, 2017. Cluster ran-
domized trial comparing school-based mass drug administra-
tion schedules in areas of western Kenya with moderate initial
prevalence of Schistosoma mansoni infections. PLoS Negl
Trop Dis 11: e0006033.
27. Olsen A, Kinung’hi S, Magnussen P, 2015. Schistosomamansoni
infection along the coast of Lake Victoria in Mwanza region,
Tanzania. Am J Trop Med Hyg 92: 1240–1244.
28. Onkanga IO,MwinziPN,MuchiriG,AndiegoK,OmedoM,Karanja
DM,Wiegand RE, SecorWE, Montgomery SP, 2016. Impact of
two rounds of praziquantel mass drug administration on
Schistosoma mansoni infection prevalence and intensity: a
comparison between community wide treatment and school
based treatment in western Kenya. Int J Parasitol 46: 439–445.
29. Phillips AE, Gazzinelli-Guimaraes PH, Aurelio HO, Ferro J, Nala R,
Clements M, King CH, Fenwick A, Fleming FM, Dhanani N,
2017. Assessing the beneﬁts of ﬁve years of different ap-
proaches to treatment of urogenital schistosomiasis: a SCORE
project in Northern Mozambique. PLoS Negl Trop Dis 11:
e0006061.
30. Tian-Bi YT et al., 2018. Interrupting seasonal transmission of
Schistosoma haematobium and control of soil-transmitted
helminthiasis in northern and central Cote d’Ivoire: a SCORE
study protocol. BMC Public Health 18: 186.
31. WHO Expert Committee, 2002. Prevention and control of schis-
tosomiasis and soil-transmitted helminthiasis. World Health
Organ Tech Rep Ser 912: 1–57.
32. Olsen A, Kinung’hi S, Magnussen P, 2018. Comparison of the
impact of different mass drug administration strategies on
infection with Schistosoma mansoni in Mwanza region,
Tanzania-a cluster-randomized controlled trial.Am J TropMed
Hyg 99: 1573–1579.
33. World Health Organization, 2011.HelminthControl in School Age
Children: a Guide for Managers of Control Programmes-2nd
ed. Geneva, Switzerland: World Health Organization.
SCHISTOSOMIASIS PERSISTENT HOTSPOTS 627
